ACHV · XBRL financial data

Achieve Life Sciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ACHV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	6,882	23,966	30,078	15,814	22,817	—
General and administrative	7,868	9,128	10,722	11,436	16,252	—
Interest income	69	17	199	825	2,356	1,495
Interest expense	—	—	1,789	2,853	2,180	819
Other income (expense)	(49)	(75)	40	(9)	(30)	(36)
Net income (loss)	(14,730)	(33,152)	(42,350)	(29,815)	(39,827)	(54,648)
Earnings per share, basic USD per share	(5.42)	(4.08)	(4.00)	(1.50)	(1.24)	(1.25)
Earnings per share, diluted USD per share	(5.42)	(4.08)	(4.00)	(1.50)	(1.24)	(1.25)
Weighted average shares, basic thousands of shares	2,719	8,120	10,593	19,827	32,071	43,595
Weighted average shares, diluted thousands of shares	2,719	8,120	10,593	19,827	32,071	43,595

Fiscal years (ACHV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	35,853	43,022	24,771	15,546	12,753	20,929
Marketable securities	—	—	—	—	21,607	15,475
Prepaid and other current assets	1,122	1,419	2,454	1,325	2,107	—
Total current assets	36,975	44,594	27,330	16,982	36,467	39,889
Property and equipment, net	42	15	4	13	8	3
Right-of-use asset	146	64	123	66	119	64
Goodwill	1,034	1,034	1,034	1,034	1,034	1,034
Total assets	40,298	47,516	29,971	19,371	38,633	41,790
Accounts payable	332	841	1,660	618	1,950	—
Total current liabilities	2,935	4,550	21,599	20,813	6,682	9,082
Lease liability, non-current	77	4	69	6	66	5
Total liabilities	3,012	19,474	21,668	20,819	17,734	20,272
Accumulated deficit	(60,434)	(93,586)	(135,936)	(165,751)	(205,578)	(260,226)
Total stockholders' equity	37,286	28,042	8,303	(1,448)	20,899	21,518
Total liabilities and equity	40,298	47,516	29,971	19,371	38,633	41,790
Common shares outstanding (cover page) thousands of shares	6,150	9,461	17,930	34,252	34,685	53,240

Fiscal years (ACHV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(14,730)	(33,152)	(42,350)	(29,815)	(39,827)	(54,648)
Stock-based compensation	1,286	2,187	3,270	3,439	5,325	8,761
Net cash from operating activities	(13,474)	(29,440)	(37,549)	(24,479)	(29,770)	(49,465)
Purchases of property and equipment	17	—	—	21	—	3
Net cash from investing activities	(17)	—	—	(21)	(21,580)	6,111
Net cash from financing activities	32,680	36,610	19,295	15,278	48,527	51,527
Net change in cash	19,189	7,169	(18,251)	(9,225)	(2,823)	8,176

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Achieve Life Sciences	47,958	not reported	(10,777)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026
Vaxart	50,929	27,185	2,778*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Ironwood Pharmaceuticals	79,127	113,041	58,276*	165.2M	—	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Milestone Pharmaceuticals	169,728	559	(22,714)*	124.5M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Assembly Biosciences	32,286	not reported	(15,488)*	20.4M	20.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.